623553-27-5 Usage
Molecular structure
2-[2-(1,3-Benzoxazol-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione consists of a benzoxazole ring and an isoindole-dione moiety, which contribute to its unique properties and potential applications.
Pharmaceutical industry
It can be used as a building block for the synthesis of new drug molecules or as an intermediate in the production of dyes and pigments.
Materials science and optoelectronics
Its structure suggests potential use as a fluorescent probe or as a photoactive compound for various applications.
Need for further research
More research and analysis are required to fully understand the potential uses and properties of 2-[2-(1,3-Benzoxazol-2-yl)ethyl]-1H-isoindole-1,3(2H)-dione.
Check Digit Verification of cas no
The CAS Registry Mumber 623553-27-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,3,5,5 and 3 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 623553-27:
(8*6)+(7*2)+(6*3)+(5*5)+(4*5)+(3*3)+(2*2)+(1*7)=145
145 % 10 = 5
So 623553-27-5 is a valid CAS Registry Number.
623553-27-5Relevant articles and documents
Synthesis and pharmacological characterization of a new benzoxazole derivative as a potent 5-HT3 receptor agonist
Lopez-Tudanca, Pedro Luis,Labeaga, Luis,Innerarity, Ana,Alonso-Cires, Luisa,Tapia, Ines,Mosquera, Ramon,Orjales, Aurelio
, p. 2709 - 2714 (2003)
N-(2-Benzoxazol-2-yl-ethyl)-guanidine hydrochloride (10) was synthesized and pharmacologically tested. This compound showed high affinity for the 5-HT3 receptor (Ki=0.77 nM) and potently triggered the von Bezold-Jarisch reflex (BJR) in rats with an ED50=0.52 μg/kg iv and intrinsic activity next to 1 (i.a.=0.94). This stimulant effect was abolished by pretreatment with the 5-HT3 receptor antagonist granisetron and was subject to a rapid and pronounced tachyphylaxis, due to desensitization of the peripheric cardiac 5-HT3 receptor. Consequently, 10 acts as an in vivo 5-HT3 antagonist inhibiting the BJR responses evoked by submaximal doses of 5-HT with an ID50=5.8 μg/kg iv.
